Cara Therapeutics Inc. (CARA) announced Wednesday morning that it has licensed worldwide rights, excluding the U.S., Japan and South Korea, to commercialize KORSUVA injection, for the treatment of pruritus in dialysis patients, to Vifor Fresenius Medical Care Renal Pharma.
from RTT - Before the Bell https://ift.tt/2xbdbrO
via IFTTT
No comments:
Post a Comment